- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00388115
Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ
A Pilot Study of Radiofrequency Ablation of Early Invasive and In Situ Breast Cancer
RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Giving radiofrequency ablation before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This clinical trial is studying how well radiofrequency ablation followed by surgery works in treating patients with early invasive breast cancer or ductal carcinoma in situ.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES:
Primary
- Determine the effectiveness of radiofrequency ablation (RFA), in terms of amount of tumor coagulated and viable cell count, in patients with early invasive breast cancer or low- or intermediate-grade ductal carcinoma in situ.
Secondary
- Determine the size, configuration, and pathological features of human breast tumors after treatment with RFA.
- Determine whether RFA energy applied to breast cancer will result in cancer cell death.
- Determine whether tumor-free margins are achieved by RFA in these patients.
- Determine the rate of acute toxicities to skin after surgery in patients treated with this regimen.
OUTLINE: This is a pilot study.
- Pre-radiofrequency ablation (RFA) procedures: Patients undergo staging by MRI assessment to determine the size of their tumor. Patients with nonpalpable lesions must undergo placement of a metallic clip in the center of their tumor and a hook wire to guide surgical excision by intraoperative ultrasound imaging. Patients with invasive breast cancer undergo axillary lymph node dissection or sentinel lymph node biopsy (SLNB) for axillary lymph node staging. Patients with ductal carcinoma in situ proceed directly to RFA/resection since they do not require axillary staging.
- RFA: Patients undergo RFA comprising insertion of a multiple-needle electrode into the breast tumor under direct guidance of ultrasonography and the metallic clip placed preoperatively in the lesion.
- Surgical resection of RFA area: After RFA is completed, the electrode is removed and patients undergo wide local excision of the residual tumor or mastectomy.
After completion of study therapy, patients are followed periodically for up to 4 months.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
California
-
Sacramento, California, États-Unis, 95817
- University of California Davis Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Females of ages ≥18 years.
- Core biopsy proven invasive breast cancer OR
- Core biopsy proven low or intermediate grade DCIS.
- Tumor less than or equal to 2.0 cm in diameter.
- No prior surgical treatment for breast cancer within 30 days.
- Life expectancy of > 10 years, not including the diagnosis of cancer.
- ECOG performance status of 0-2.
- Informed consent given.
- Multifocal invasive breast cancer patients are eligible. All tumors that are palpable or visualized by USS can be treated.
Exclusion Criteria:
- Male subjects.
- Ages < 18 years.
- Breast tumor > 2.0 cm in diameter.
- Evidence of distant metastatic disease.
- Evidence of diffuse calcification suggestive of extensive or multifocal DCIS.
- High grade DCIS or presence of comedo-necrosis because these lesions can be associated with invasive breast cancer, which would go undetected if the lesion is entirely destroyed by the RF ablation.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: RFA prior to surgery
|
Standard of care lumpectomy or mastectomy following RFA
Standard of care lumpectomy or mastectomy following RFA
A small diameter needle is inserted through the skin and directly into the tumor for the purpose of supplying RF current.
Initial power of the RF generator will start at 5-10 watts.
The power will increase by 5-10 watts every minute until impedance of the system automatically stops the RF treatment.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Number and proportion of patients with viable cancer cells remaining in the resected specimen as measured by enzyme cell viability analysis and amount of tumor coagulated at post-treatment biopsy
Délai: At completion of study
|
At completion of study
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Number and proportion of patients with uncoagulated tumor remnant at post-treatment biopsy
Délai: At completion of study
|
At completion of study
|
Number and proportion of patients with and without tumor in the margin
Délai: At completion of study
|
At completion of study
|
Rate of acute skin toxicity
Délai: At completion of study
|
At completion of study
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Vijay Khatri, MD, University of California, Davis
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CDR0000505536
- P30CA093373 (Subvention/contrat des NIH des États-Unis)
- UCD-123 (Autre identifiant: University of California, Davis - Cancer Center)
- UCD-200210277-6 (Autre identifiant: University of California, Davis - IRB)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer du sein
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie
Essais cliniques sur conventional surgery
-
ARCAGY/ GINECO GROUPRecrutementCancer de l'ovaire stade IIIC | Cancer de l'ovaire stade IV | Cancer de l'ovaire stade IIIbFrance
-
University Hospital Inselspital, BerneComplétéEssai contrôlé randomisé | Shunt péritonéal ventriculaire | Complications de shunt | Échec du shuntSuisse
-
Dr. Faruk SemizInscription sur invitation
-
University of TriesteComplété
-
National Cancer Centre, SingaporeComplétéMaladies thyroïdiennesSingapour
-
Kocaeli Derince Education and Research HospitalKocaeli UniversityInconnueRécupération améliorée après la chirurgie | Opération à coeur ouvertTurquie
-
St. Joseph's Healthcare HamiltonHamilton Academic Health Sciences OrganizationComplétéCancer du poumon, non à petites cellulesCanada
-
Ethicon Endo-SurgeryRésiliéObésitéÉtats-Unis, Allemagne
-
The Second Hospital of Shandong UniversityRecrutementChirurgie pulmonaire avec récupération améliorée VS. Chirurgie pulmonaire sans récupération assistéeCancer du poumon | Opération | ERASChine
-
University of Illinois at ChicagoEthicon Endo-SurgeryRetiréMaladies du côlon et du rectumÉtats-Unis